Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Renal and cardiovascular role of the neuropeptide Y Y1 receptor in ischaemic heart failure rats

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hot and cold cognitive disturbances in antidepressant-free patients with major depressive disorder: a NeuroPharm study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jaya Prabhakaran
  • Christine DeLorenzo
  • Francesca Zanderigo
  • Gitte M Knudsen
  • Nic Gilling
  • Mali Pratap
  • Matthew J Jorgensen
  • James Daunais
  • Jay R Kaplan
  • Ramin V Parsey
  • J John Mann
  • Dileep Kumar
View graph of relations

PURPOSE: 5-HT2AR exists in high and low affinity states. Agonist PET tracers measure binding to the active high affinity site and thus provide a functionally relevant measure of the receptor. Limited in vivo data have been reported so far for a comparison of agonist versus antagonist tracers for 5-HT2AR used as a proof of principle for measurement of high and low affinity states of this receptor. We compared the in vivo binding of [11C]CIMBI-5, a 5-HT2AR agonist, and of the antagonist [11C]M100907, in monkeys and baboons.

METHODS: [11C]CIMBI-5 and [11C]M100907 baseline PET scans were performed in anesthetized male baboons (n=2) and male vervet monkeys (n=2) with an ECAT EXACT HR+ and GE 64-slice PET/CT Discovery VCT scanners. Blocking studies were performed in vervet monkeys by pretreatment with MDL100907 (0.5 mg/kg, i.v.) 60 minutes prior to the scan. Regional distribution volumes and binding potentials were calculated for each ROI using the likelihood estimation in graphical analysis and Logan plot, with either plasma input function or reference region as input, and simplified reference tissue model approaches.

RESULTS: PET imaging of [11C]CIMBI-5 in baboons and monkeys showed the highest binding in 5-HT2AR-rich cortical regions, while the lowest binding was observed in cerebellum, consistent with the expected distribution of 5-HT2AR. Very low free fractions and rapid metabolism were observed for [11C]CIMBI-5 in baboon plasma. Binding potential values for [11C]CIMBI-5 were 25-33% lower than those for [11C]MDL100907 in the considered brain regions.

CONCLUSION: The lower binding potential of [11C]CIMBI-5 in comparison to [11C]MDL100907 is likely due to the preferential binding of the former to the high affinity site in vivo in contrast to the antagonist, [11C]MDL100907, which binds to both high and low affinity sites.

Original languageEnglish
JournalJournal of Pharmacy and Pharmacology
Volume22
Issue number1
Pages (from-to)352-364
Number of pages13
ISSN0022-3573
DOIs
Publication statusPublished - 2019

ID: 58467071